NEW YORK, September 6, 2017 /PRNewswire/ --
If you want a Stock Review on CELG, DVAX, KERX, or MBRX then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. Pre-market, DailyStockTracker.com explores the Biotech space, which consists of companies engaged in the research and development of new drugs, medical devices, and procedures. The industry includes the manufacturing and marketing of drugs as a result of direct research and development. For assessment this morning are these four stocks: Celgene Corp. (NASDAQ: CELG), Dynavax Technologies Corp. (NASDAQ: DVAX), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), and Moleculin Biotech Inc. (NASDAQ: MBRX). Learn more about these stocks by downloading their comprehensive and free reports from DailyStockTracker.com member's area at:
http://dailystocktracker.com/register/
Celgene
On Tuesday, shares in Summit, New Jersey headquartered Celgene Corp. saw a slight decline of 0.02%, ending the day at $139.35. The stock recorded a trading volume of 4.19 million shares, which was above its three months average volume of 3.84 million shares. The Company's shares have advanced 1.94% in the last one month, 19.22% over the previous three months, and 20.39% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 4.47% and 12.98%, respectively. Moreover, shares of Celgene, which discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide, have a Relative Strength Index (RSI) of 67.72.
On August 24th, 2017, Celgene announced that management will provide an overview of the Company at the Baird Global Healthcare Conference on September 06th, 2017, at 3:45 p.m. ET in New York City. The Company will also present at the Morgan Stanley Global Healthcare Unplugged Conference on September 13th, 2017, at 9:20 a.m. ET in New York City. CELG complete research report is just a click away at:
http://dailystocktracker.com/registration/?symbol=CELG
Dynavax Technologies
Shares in Berkeley, California headquartered Dynavax Technologies Corp. ended the day 2.79% higher at $18.45 with a total trading volume of 1.41 million shares. In the last month and the previous three months, the stock has gained 11.48% and 167.39%, respectively. Additionally, the Company's shares have skyrocketed 367.09% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 39.40% and 155.72%, respectively. Furthermore, shares of Dynavax Technologies, which focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation, have an RSI of 68.48.
On August 15th, 2017, Dynavax Technologies announced the completion of an underwritten public offering of 5,750,000 shares of its common stock, including 750,000 shares sold pursuant to the full exercise of an over-allotment option previously granted to the underwriters. All of the shares were offered by the Company at a price to the public of $15.00 per share. The complimentary report on DVAX can be downloaded at:
http://dailystocktracker.com/registration/?symbol=DVAX
Keryx Biopharmaceuticals
At the close of trading on Tuesday, shares in Boston, Massachusetts headquartered Keryx Biopharmaceuticals Inc. finished 0.13% lower at $7.59. A total volume of 2.23 million shares was traded, which was above their three months average volume of 1.32 million shares. The stock has advanced 8.90% in the last one month, 16.95% over the previous three months, and 29.52% on an YTD basis. The Company's shares are trading above their 50-day and 200-day moving averages by 6.17% and 23.18%, respectively. Additionally, shares of Keryx Biopharma, which focuses on providing medicines for patients with renal disease in the US, have an RSI of 64.59. Sign up for your complimentary research report on KERX at:
http://dailystocktracker.com/registration/?symbol=KERX
Moleculin Biotech
Houston, Texas headquartered Moleculin Biotech Inc.'s shares recorded a trading volume of 272,689 shares at the end of yesterday's session. The stock closed the day 1.96% lower at $2.50. The Company's shares have advanced 212.50% in the previous three months and 9.65% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 11.32% and 51.87%, respectively. Additionally, shares of Moleculin Biotech, which focuses on the development of anti-cancer drug candidates, have an RSI of 54.24.
On August 31st, 2017, Moleculin Biotech announced that it will be featured as a presenting company at the 19th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held on September 10th, 2017 to September 12th, 2017 at Lotte New York Palace Hotel in New York City. Get free access to your research report on MBRX at:
http://dailystocktracker.com/registration/?symbol=MBRX
--
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@dailystocktracker.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
http://dailystocktracker.com/disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: contact@dailystocktracker.com
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE dailystocktracker.com
